Van de site van TLC:
TLC and Ablynx entered into a Feasibility Study Agreement
2014/4/17 ?? 12:00:00
Taiwan Liposome Company (TLC, 4152:TT) and Ablynx NV (ABLX) have entered into an agreement to research actively targeted nanoparticles for potential treatments across different indications combining TLC’s immunoliposome drug delivery platform with Ablynx’s Nanobody® targeting agents.
Immunoliposome combines TLC’s core technology of liposomal encapsulated drug delivery system (DDS) with Ablynx’s Nanobodies to deliver payloads intracellularly. Targeted immunoliposome nanoparticles will pass through leaky vasculatures of blood vessels and Nanobodies will target overexpressed receptors, resulting in receptor-complex internalization and subsequent intracellular release of over 10,000 payload molecules. This mechanism will enable the delivery of cytotoxic compound inside tumor cells for oncology indications, resulting in extensive tumor reduction through necrosis or apoptosis.
Dr. Keelung Hong, Chairman and CEO of TLC said: "TLC has been dedicated to the development of drug delivery systems since our establishment, and we are very excited to work with Ablynx in exploring the opportunity of bringing a more effective way of cancer treatment to benefit patients."
George Yeh, President of TLC further commented: "Antibody drug conjugates brought much excitement to the healthcare industry by combining the targeting specificity of antibodies with the efficacy of cytotoxic compounds. Our immunoliposome platform can drastically enhance the therapeutic value by carrying a much higher payload amount. This collaboration with Ablynx marks the starting point of infinite development possibilities for this technology platform."
TLC has successfully applied its liposomal drug delivery systems to oncology compounds including doxorubicin and vinca alkaloids. Ligands such as antibodies, Fabs, scFvs, proteins/peptides can all be used to achieve the targeting effect.